IDEAYA生物科学公司开始针对B7H3和PTK7的IDE034一期临床试验，用于晚期实体瘤IDEAYA Biosciences Begins Phase 1 Trial of IDE034 Targeting B7H3 and PTK7 in Advanced Solid Tumors

动脉网

昨天

by GOAI由GOAI生成Share To分享到IDEAYA Biosciences has initiated its Phase 1 clinical trial for IDE034, a bispecific antibody-drug conjugate (ADC) targeting B7H3 and PTK7. The company announced that the ...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2614511540"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2614511540\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2614511540?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-02-25 20:07","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2614511540","market":"us","top_or_hot":-1,"title":"IDEAYA生物科学公司开始针对B7H3和PTK7的IDE034一期临床试验，用于晚期实体瘤IDEAYA Biosciences Begins Phase 1 Trial of IDE034 Targeting B7H3 and PTK7 in Advanced Solid Tumors","media":"动脉网","content":"<div>\n<p>by GOAI由GOAI生成Share To分享到IDEAYA Biosciences has initiated its Phase 1 clinical trial for IDE034, a bispecific antibody-drug conjugate (ADC) targeting B7H3 and PTK7. The company announced that the ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225201021a4c73b9c&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IDEAYA生物科学公司开始针对B7H3和PTK7的IDE034一期临床试验，用于晚期实体瘤IDEAYA Biosciences Begins Phase 1 Trial of IDE034 Targeting B7H3 and PTK7 in Advanced Solid Tumors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIDEAYA生物科学公司开始针对B7H3和PTK7的IDE034一期临床试验，用于晚期实体瘤IDEAYA Biosciences Begins Phase 1 Trial of IDE034 Targeting B7H3 and PTK7 in Advanced Solid Tumors\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-25 20:07 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225201021a4c73b9c&s=b><strong>动脉网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>by GOAI由GOAI生成Share To分享到IDEAYA Biosciences has initiated its Phase 1 clinical trial for IDE034, a bispecific antibody-drug conjugate (ADC) targeting B7H3 and PTK7. The company announced that the ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225201021a4c73b9c&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225201021a4c73b9c&s=b","article_id":"2614511540","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225201021a4c73b9c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2614511540","pubTimestamp":1772021220,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"IDE034 is described as a potential first-in-class ADC that incorporates a topoisomerase I inhibitor payload..IDE034被描述为一种潜在的同类首个ADC，它包含拓扑异构酶I抑制剂有效载荷。The Phase 1 trial aims to assess IDE034 in patients with advanced solid tumors. According to the announcement, the drug’s dual-targeting mechanism focuses on B7H3 and PTK7, two proteins associated with tumor growth and progression. This approach seeks to enhance therapeutic precision while minimizing off-target effects.一期试验旨在评估IDE034在晚期实体瘤患者中的效果。根据公告，该药物的双重靶向机制聚焦于B7H3和PTK7，这两种与肿瘤生长和进展相关的蛋白质。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","IDYA":"IDEAYA Biosciences"},"translate_title":"IDEAYA Biosciences begins Phase I clinical trial of IDE034 targeting B7H3 and PTK7 for advanced solid tumors IDEAYA Biosciences Begins Phase 1 Trial of IDE034 Targeting B7H3 and PTK7 in Advanced Solid Tumors","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IDYA":1.5},"content_text":"by GOAI由GOAI生成Share To分享到IDEAYA Biosciences has initiated its Phase 1 clinical trial for IDE034, a bispecific antibody-drug conjugate (ADC) targeting B7H3 and PTK7. The company announced that the first patient has been enrolled in this study, marking a significant step in evaluating the safety, tolerability, and preliminary efficacy of this investigational therapy.IDEAYA Biosciences 已启动其针对 B7H3 和 PTK7 的双特异性抗体药物偶联物 (ADC) IDE034 的 1 期临床试验。该公司宣布，首位患者已入组此项研究，标志着在评估这一在研疗法的安全性、耐受性和初步疗效方面迈出了重要一步。IDE034 is described as a potential first-in-class ADC that incorporates a topoisomerase I inhibitor payload..IDE034被描述为一种潜在的同类首个ADC，它包含拓扑异构酶I抑制剂有效载荷。The Phase 1 trial aims to assess IDE034 in patients with advanced solid tumors. According to the announcement, the drug’s dual-targeting mechanism focuses on B7H3 and PTK7, two proteins associated with tumor growth and progression. This approach seeks to enhance therapeutic precision while minimizing off-target effects.一期试验旨在评估IDE034在晚期实体瘤患者中的效果。根据公告，该药物的双重靶向机制聚焦于B7H3和PTK7，这两种与肿瘤生长和进展相关的蛋白质。这种方法力求提高治疗的精准性，同时减少脱靶效应。The study will collect data on dosage levels, adverse events, pharmacokinetics, and early signs of anti-tumor activity. Further updates on the trial’s progress are expected as additional patients are enrolled and results become available..该研究将收集有关剂量水平、不良事件、药代动力学和抗肿瘤活性早期迹象的数据。随着更多患者入组以及结果的出炉，预计会有进一步的试验进展更新。Newsflash | Powered by GeneOnline AI新闻快讯 | 由GeneOnline AI提供支持Source: GO-AI-ne1来源：GO-AI-ne1For any suggestion and feedback, please contact us.如有任何建议和反馈，请联系我们。Date: February 25, 2026日期：2026年2月25日©www.geneonline.com All rights reserved. Collaborate with us:©www.geneonline.com 版权所有。与我们合作：[email protected]电子邮件地址Author作者GOAIGOAIRelated Post相关文章","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}